A 3-way cross-over, randomized, placebo-controlled, double-blind, multicenter study to assess the pharmacologic effects of a 7-day exposure to darifenacin 15 mg o.d. and tolterodine ER [extended release] 4 mg o.d on cardiovascular parameters in healthy subjects 50 years of age and older.
Phase of Trial: Phase IV
Latest Information Update: 26 Oct 2007
At a glance
- Drugs Darifenacin; Tolterodine
- Indications Overactive bladder
- Focus Pharmacodynamics
- Sponsors Novartis
- 26 Oct 2007 Status changed from recruiting to completed.
- 10 Jan 2007 New trial record.